Form 4: Halozyme Therapeutics SVP, Chief Technical Officer, Michael J. LaBarre, Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- On February 20, 2025, Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, was granted options to purchase 11,902 shares of common stock at an exercise price of $57.44.
- These options vest one-fourth on February 20, 2026, and then 1/48th monthly thereafter.
- LaBarre also received 11,230 restricted stock units (RSUs) which vest one-fourth on each anniversary of the grant date, starting February 20, 2026.
- Following these transactions, LaBarre directly owns options for 11,902 shares and 11,230 RSUs.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is therefore slightly positive.
Positives
- The grant of stock options and RSUs to a key executive aligns their interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the executive.
Industry Context
Stock option and RSU grants are common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in publicly traded biotech companies like Halozyme.
- Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation to align executive interests with shareholder value.
Stakeholder Impact
- Shareholders: The grants align executive interests with shareholder value.
- Employees: The grants can serve as a motivation for other employees.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of stock option and RSU grant |
| 02/20/2026 | First vesting date for both stock options and RSUs |
| 02/20/2035 | Expiration date for the stock options |
| 02/21/2025 | Date of signature for the report |
Keywords
Form 4, Halozyme Therapeutics, Michael J. LaBarre, Stock Options, Restricted Stock Units, Beneficial Ownership, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.